CN107693538B - 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 - Google Patents
含金团簇的物质在制备预防和治疗帕金森症药物中的应用 Download PDFInfo
- Publication number
- CN107693538B CN107693538B CN201710597787.8A CN201710597787A CN107693538B CN 107693538 B CN107693538 B CN 107693538B CN 201710597787 A CN201710597787 A CN 201710597787A CN 107693538 B CN107693538 B CN 107693538B
- Authority
- CN
- China
- Prior art keywords
- gold
- ligand
- solution
- gold cluster
- cluster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G7/00—Compounds of gold
- C01G7/003—Preparation involving a liquid-liquid extraction, an adsorption or an ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/02—Thiols having mercapto groups bound to acyclic carbon atoms
- C07C321/04—Thiols having mercapto groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/26—Thiols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C5/00—Alloys based on noble metals
- C22C5/02—Alloys based on gold
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0545—Dispersions or suspensions of nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/14—Treatment of metallic powder
- B22F1/145—Chemical treatment, e.g. passivation or decarburisation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/14—Treatment of metallic powder
- B22F1/148—Agglomerating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2999/00—Aspects linked to processes or compositions used in powder metallurgy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/90—Other morphology not specified above
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Ceramic Engineering (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mechanical Engineering (AREA)
- Microbiology (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010953800.0A CN111848471A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016106359125 | 2016-08-05 | ||
CN201610635912 | 2016-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010953800.0A Division CN111848471A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107693538A CN107693538A (zh) | 2018-02-16 |
CN107693538B true CN107693538B (zh) | 2021-05-11 |
Family
ID=61073450
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710597787.8A Active CN107693538B (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 |
CN202010953763.3A Pending CN111848470A (zh) | 2016-08-05 | 2017-07-20 | 一种含金团簇的物质及其制备方法与应用 |
CN202010953800.0A Pending CN111848471A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 |
CN201710595672.5A Active CN107684560B (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗阿兹海默病药物中的应用 |
CN201710595548.9A Active CN107684559B (zh) | 2016-08-05 | 2017-07-20 | 一种含金团簇的物质及其制备方法与应用 |
CN202010955113.2A Pending CN111848472A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗阿兹海默病药物中的应用 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010953763.3A Pending CN111848470A (zh) | 2016-08-05 | 2017-07-20 | 一种含金团簇的物质及其制备方法与应用 |
CN202010953800.0A Pending CN111848471A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 |
CN201710595672.5A Active CN107684560B (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗阿兹海默病药物中的应用 |
CN201710595548.9A Active CN107684559B (zh) | 2016-08-05 | 2017-07-20 | 一种含金团簇的物质及其制备方法与应用 |
CN202010955113.2A Pending CN111848472A (zh) | 2016-08-05 | 2017-07-20 | 含金团簇的物质在制备预防和治疗阿兹海默病药物中的应用 |
Country Status (10)
Country | Link |
---|---|
US (6) | US10729718B2 (zh) |
EP (2) | EP4000636A3 (zh) |
JP (5) | JP2019533636A (zh) |
CN (6) | CN107693538B (zh) |
AU (2) | AU2017306328B2 (zh) |
DK (1) | DK3449945T3 (zh) |
ES (1) | ES2908466T3 (zh) |
HK (1) | HK1250487A1 (zh) |
PT (1) | PT3449945T (zh) |
WO (1) | WO2018024111A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109986073B (zh) * | 2019-01-15 | 2021-06-15 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种基于超滤的金团簇快速纯化方法 |
CN114558029A (zh) * | 2019-01-16 | 2022-05-31 | 武汉广行科学研究有限公司 | 铜团簇、胸腺嘧啶修饰的透明质酸和多聚铜团簇、其制备方法和应用 |
EP3886918A4 (en) * | 2019-01-16 | 2022-03-02 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | COPPER ANOCLUSTER, THYMINE-MODIFIED HYALURONIC ACID AND POLY(COPPER ANOCLUSTER), PROCESS FOR THEIR PREPARATION AND USE |
CN110016043B (zh) * | 2019-05-10 | 2021-05-25 | 西北工业大学 | 一种具有发射白光性质的金纳米团簇及其制备方法 |
JP7311086B2 (ja) * | 2019-08-21 | 2023-07-19 | ブレイン ケミストリー ラブズ | 金属及びl-セリンを含む組成物、並びにその使用 |
WO2021072747A1 (en) * | 2019-10-18 | 2021-04-22 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Composition and method for treatment of diabetes |
CN116115637A (zh) * | 2019-10-18 | 2023-05-16 | 深圳深见医药科技有限公司 | 用于治疗糖尿病的组合物和方法 |
IT201900020724A1 (it) * | 2019-11-11 | 2021-05-11 | Univ Degli Studi Milano | Nanocluster d’oro nel trattamento atassia di Friedreich |
WO2021128292A1 (en) * | 2019-12-27 | 2021-07-01 | Wuhan Vast Conduct Science Foundation Co., Ltd. | Composition and method for treatment of multiple sclerosis |
CN115919895A (zh) * | 2019-12-27 | 2023-04-07 | 武汉广行科学研究有限公司 | 用于治疗多发性硬化症的组合物和方法 |
CN110859827A (zh) * | 2019-12-27 | 2020-03-06 | 华北水利水电大学 | 一种金纳米团簇耦合体、其制备方法及微胶囊 |
CA3164005A1 (en) | 2020-03-16 | 2020-10-28 | Taolei Sun | Gold clusters (aucs), composition and method for treatment of liver cirrhosis |
CN113398279B (zh) * | 2020-03-16 | 2022-09-20 | 武汉广行科学研究有限公司 | 用于治疗肝硬化的配体结合的金团簇,组合物和方法 |
CN113398280B (zh) * | 2020-03-16 | 2022-10-14 | 武汉广行科学研究有限公司 | 配体结合的铜团簇、含配体结合的铜团簇的配伍及其治疗肝硬化中的应用 |
CA3178004A1 (en) * | 2020-05-09 | 2021-11-18 | Taolei Sun | Treatment of adverse effects caused by atypical antipsychotics |
CN111906328B (zh) * | 2020-08-11 | 2022-10-25 | 苏州大学 | 一种177Lu标记的金纳米团簇及其制备方法和应用 |
CN114432340B (zh) * | 2020-11-03 | 2023-06-23 | 北京工业大学 | 一种Au与抗凋亡蛋白拮抗肽的复合物制备以及协同诱导肿瘤细胞凋亡的应用 |
WO2022110022A1 (en) | 2020-11-27 | 2022-06-02 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Gold clusters, compositions, and methods for treatment of cerebral ischemic stroke |
CN113199035B (zh) * | 2021-04-21 | 2022-07-12 | 武汉理工大学 | 一种金纳米颗粒-金纳米团簇复合材料及其制备方法和应用 |
US20240131182A1 (en) * | 2021-04-25 | 2024-04-25 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Gold clusters, compositions, and methods for treatment of depression |
CN115317510B (zh) * | 2021-04-25 | 2023-12-01 | 深圳深见医药科技有限公司 | 治疗抑郁症的金团簇、组合物和方法 |
CN113358528B (zh) * | 2021-06-08 | 2022-06-17 | 山东大学 | 一种基于悬滴法检测乙酰胆碱酯酶及其抑制剂的方法 |
CN114472915B (zh) * | 2022-01-19 | 2023-07-28 | 东南大学 | 一种可拉伸仿生簇状金纳米线薄膜及制备方法与应用 |
WO2023137671A1 (en) * | 2022-01-20 | 2023-07-27 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | L-n-isobutyryl cysteine (l-nibc) -bound gold cluster au 15 (l-nibc) 13, compositions and applications thereof |
CN115121244B (zh) * | 2022-06-17 | 2023-04-25 | 武汉理工大学 | 硼氢化钠原位还原制备石墨烯负载金团簇纳米复合材料的方法及应用 |
CN115870494B (zh) * | 2022-10-20 | 2024-05-28 | 武汉理工大学 | 一种戊烯酸-异丙基丙烯酰胺共聚物修饰超小金纳米材料及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573923A (zh) * | 2010-01-21 | 2012-07-11 | 光州科学技术院 | 皮肤渗透性、细胞摄取率及肿瘤传递性增强的纳米载体 |
CN103933583A (zh) * | 2014-04-14 | 2014-07-23 | 上海交通大学 | 抑制mgc-803细胞的手型金纳米团簇的制备及其用途 |
CN104667297A (zh) * | 2015-02-05 | 2015-06-03 | 华南师范大学 | 一种具有抑制神经细胞凋亡作用的金纳米粒复合物及其应用 |
CN105267235A (zh) * | 2014-07-16 | 2016-01-27 | 华上生技医药股份有限公司 | 纳米金属在促进神经突生长和治疗和/或预防神经病症中的用途 |
CN105527267A (zh) * | 2016-01-30 | 2016-04-27 | 山西大学 | 一种红色荧光金纳米团簇及其制备方法和应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645464B1 (en) * | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
JP3859882B2 (ja) | 1998-09-14 | 2006-12-20 | 株式会社リコー | 新規なオリゴフェロセニレン誘導体及び電気化学的に活性なクラスター薄膜の製造方法 |
JP3650582B2 (ja) * | 1998-11-30 | 2005-05-18 | ナノスフェアー インコーポレイテッド | ポリマー−ナノ粒子ハイブリッド粒子 |
WO2002001230A2 (en) * | 2000-06-23 | 2002-01-03 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of protein aggregation |
AU2001249459A1 (en) * | 2000-03-24 | 2001-10-08 | The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Scaffold-organized clusters and electronic devices made using such clusters |
US7413770B2 (en) * | 2002-08-01 | 2008-08-19 | E.I. Du Pont De Nemours And Company | Ethylene glycol monolayer protected nanoparticles |
JP2007297281A (ja) * | 2004-07-29 | 2007-11-15 | Ainobekkusu Kk | 体内活性酸素消去剤 |
EP1793863B1 (en) * | 2004-10-01 | 2017-04-12 | Midatech Ltd. | Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells |
WO2008130296A1 (en) * | 2007-04-18 | 2008-10-30 | Biochromix Ab | Binding of pathological forms of proteins using conjugated polyelectrolytes |
CN101947235A (zh) * | 2007-04-18 | 2011-01-19 | 比奥克罗密克斯药业有限公司 | 共轭聚电解质的医药用途 |
CN101502880B (zh) * | 2009-03-02 | 2011-04-13 | 浙江大学 | 亚纳米金团簇分子的制备方法 |
KR102051248B1 (ko) * | 2009-07-08 | 2019-12-02 | 클레네 나노메디슨, 인크. | 의학적 치료를 위한 신규한 금계 나노결정 및 이를 위한 전기화학 제조 방법 |
CN101905328B (zh) * | 2010-07-16 | 2011-12-21 | 浙江大学 | 一种水溶性Au10纳米团簇分子的制备方法 |
US10012653B2 (en) * | 2011-06-15 | 2018-07-03 | Board Of Regents, The University Of Texas System | Nanoparticles for targeting acid tumor microenvironments |
US9689826B2 (en) * | 2012-03-11 | 2017-06-27 | Technion Research And Development Foundation Ltd. | Detection of chronic kidney disease and disease progression |
ITRM20120350A1 (it) * | 2012-07-19 | 2014-01-20 | Univ Degli Studi Milano | Nanocostrutti con attività farmacologica. |
CA3153463A1 (en) * | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
EP2958553B1 (en) * | 2013-02-19 | 2018-02-14 | National Health Research Institutes | Caged platinum nanoclusters for anticancer chemotherapeutics |
IN2013DE00866A (zh) * | 2013-03-22 | 2015-07-10 | Council Scient Ind Res | |
JP6634626B2 (ja) * | 2013-11-05 | 2020-01-22 | エレーナ モロカノヴァElena MOLOKANOVA | 受容体およびイオンチャネルの位置特異的サブタイプの調節のためのナノ構造物複合体 |
CN105079782A (zh) * | 2014-05-13 | 2015-11-25 | 中国医学科学院放射医学研究所 | 一种金团簇作为肿瘤放疗增敏剂和ct造影剂的应用及其药物制剂 |
CN104215760B (zh) * | 2014-09-13 | 2016-06-29 | 福建医科大学 | 基于荧光金纳米团簇的脲酶抑制剂测定方法 |
CN104689344B (zh) * | 2015-02-03 | 2017-06-16 | 东南大学 | 应用于老年痴呆症的早期快速检测及其多模态成像的影像制剂 |
CN105061561B (zh) * | 2015-07-21 | 2019-03-26 | 天津大学 | 用于抑制β淀粉样蛋白聚集的多肽和多肽功能化的金纳米粒子及制备和应用 |
TWI542710B (zh) * | 2015-09-30 | 2016-07-21 | 胡宇光 | 光致螢光金奈米粒子及其製造方法 |
-
2017
- 2017-07-20 EP EP21218128.3A patent/EP4000636A3/en active Pending
- 2017-07-20 CN CN201710597787.8A patent/CN107693538B/zh active Active
- 2017-07-20 CN CN202010953763.3A patent/CN111848470A/zh active Pending
- 2017-07-20 JP JP2018569147A patent/JP2019533636A/ja active Pending
- 2017-07-20 CN CN202010953800.0A patent/CN111848471A/zh active Pending
- 2017-07-20 CN CN201710595672.5A patent/CN107684560B/zh active Active
- 2017-07-20 CN CN201710595548.9A patent/CN107684559B/zh active Active
- 2017-07-20 DK DK17836293.5T patent/DK3449945T3/da active
- 2017-07-20 WO PCT/CN2017/093671 patent/WO2018024111A1/zh unknown
- 2017-07-20 US US16/084,553 patent/US10729718B2/en active Active
- 2017-07-20 EP EP17836293.5A patent/EP3449945B1/en active Active
- 2017-07-20 ES ES17836293T patent/ES2908466T3/es active Active
- 2017-07-20 CN CN202010955113.2A patent/CN111848472A/zh active Pending
- 2017-07-20 PT PT178362935T patent/PT3449945T/pt unknown
- 2017-07-20 AU AU2017306328A patent/AU2017306328B2/en active Active
-
2018
- 2018-08-01 HK HK18109915.3A patent/HK1250487A1/zh unknown
- 2018-09-13 US US16/129,896 patent/US20190030070A1/en not_active Abandoned
- 2018-09-13 US US16/129,884 patent/US11058717B2/en active Active
-
2019
- 2019-04-28 US US16/396,727 patent/US11000543B2/en active Active
-
2021
- 2021-04-05 US US17/222,310 patent/US20210220395A1/en active Pending
- 2021-04-05 US US17/222,229 patent/US20210220394A1/en active Pending
- 2021-04-19 JP JP2021070600A patent/JP7290881B2/ja active Active
- 2021-04-19 JP JP2021070595A patent/JP7217046B2/ja active Active
- 2021-04-19 JP JP2021070598A patent/JP7290880B2/ja active Active
- 2021-08-02 AU AU2021211975A patent/AU2021211975B2/en active Active
-
2023
- 2023-01-16 JP JP2023004293A patent/JP2023061928A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573923A (zh) * | 2010-01-21 | 2012-07-11 | 光州科学技术院 | 皮肤渗透性、细胞摄取率及肿瘤传递性增强的纳米载体 |
CN103933583A (zh) * | 2014-04-14 | 2014-07-23 | 上海交通大学 | 抑制mgc-803细胞的手型金纳米团簇的制备及其用途 |
CN105267235A (zh) * | 2014-07-16 | 2016-01-27 | 华上生技医药股份有限公司 | 纳米金属在促进神经突生长和治疗和/或预防神经病症中的用途 |
CN104667297A (zh) * | 2015-02-05 | 2015-06-03 | 华南师范大学 | 一种具有抑制神经细胞凋亡作用的金纳米粒复合物及其应用 |
CN105527267A (zh) * | 2016-01-30 | 2016-04-27 | 山西大学 | 一种红色荧光金纳米团簇及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
Glutathione-protected gold clusters revisited: bridging the gap between gold(I)-thiolate complexes and thiolate-protected gold nanocrystals;Negishi Y等;《J Am Chem Soc》;20050413;第127卷(第14期);摘要、第5263页右边栏第3段 * |
Study of Wild-Type α-Synuclein Binding and Orientation on Gold Nanoparticles;Yang JA等;《Langmuir》;20130325;第29卷(第14期);摘要,第4603-4615页 * |
手性金纳米团簇:一种新型近红外荧光探针;高冠斌等;《化学学报》;20160415(第74期);摘要,第364页左边栏第3段-第367页左边栏第1段 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107693538B (zh) | 含金团簇的物质在制备预防和治疗帕金森症药物中的应用 | |
US20210046107A1 (en) | Use of fullerene structure in preparation of medicaments for treating parkinson's disease | |
CN111568922B (zh) | 治疗非典型抗精神病药物引起的不良反应 | |
US20230158065A1 (en) | Treatment of adverse effects caused by atypical antipsychotics | |
US20220401573A1 (en) | Composition and method for treatment of multiple sclerosis | |
US20240131182A1 (en) | Gold clusters, compositions, and methods for treatment of depression | |
WO2022110022A1 (en) | Gold clusters, compositions, and methods for treatment of cerebral ischemic stroke | |
CN111317745B (zh) | 水溶性富勒烯结构在制备治疗帕金森病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1250488 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 518058 A3311, Building 9, Zone 2, Shenzhen Bay Science and Technology Ecological Park, No. 3609, Baishi Road, High tech District Community, Yuehai Street, Nanshan District, Shenzhen, Guangdong Patentee after: SHENZHEN PROFOUND-VIEW PHARMA TECH Co.,Ltd. Address before: 518000 room 718, bus building, Fuhua Road, Futian street, Futian District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN PROFOUND-VIEW PHARMA TECH Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |